诺泰生物: 诺泰生物：关于收到《行政处罚事先告知书》的公告

Core Viewpoint - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for violations related to information disclosure and fraudulent issuance of shares, particularly concerning the 2021 annual report which inflated revenue and profit figures [1][2][6]. Group 1: Violations and Findings - The 2021 annual report of Nuotai Biopharmaceutical contained false records, inflating revenue by 30 million yuan and profit by 25.9516 million yuan, which accounted for 20.64% of the reported total profit for that period [2][4]. - The actual controller, Zhao Dezhong, and other executives were involved in orchestrating the fraudulent activities, including the arrangement of a technology transfer that lacked commercial substance [2][3][5]. - The company also fabricated significant false content in its public offering documents, violating multiple regulations, including the Securities Law [6][8]. Group 2: Proposed Penalties - The CSRC plans to impose a fine of 43.4 million yuan on Nuotai Biopharmaceutical for the false content in its public offering documents and additional fines on individual executives, including 6 million yuan for Zhao Dezhong [7][8]. - Specific penalties include 1.3 million yuan for Zhao Dezhong, 500,000 yuan for Zhao Deyi, and 330,000 yuan for Jin Fuqiang, among others [8][9]. - The company is required to correct its violations and has been warned about the consequences of its actions, which may lead to further regulatory scrutiny [7][10]. Group 3: Company Response and Future Actions - The company acknowledges the violations and expresses a commitment to rectify the issues, enhance compliance training, and improve operational standards to protect shareholder interests [10][11]. - Nuotai Biopharmaceutical will continue to monitor the situation and fulfill its disclosure obligations as required by law [10].